Titrating Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous Nephropathy | Zendy

Paolo Cravedi | Zendy; Piero Ruggenenti | Zendy; Maria Chiara Sghirlanzoni | Zendy; Giuseppe Remuzzi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Titrating Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous Nephropathy

Author(s) -

Paolo Cravedi,

Piero Ruggenenti,

Maria Chiara Sghirlanzoni,

Giuseppe Remuzzi

Publication year - 2007

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.01180307

Subject(s) - rituximab , medicine , membranous nephropathy , cd20 , regimen , nephrotic syndrome , single center , adverse effect , gastroenterology , immunology , glomerulonephritis , antibody , kidney

Rituximab, given in four weekly doses, is a promising treatment for idiopathic membranous nephropathy and other immune-mediated diseases and lymphoproliferative disorders. This multidose regimen, however, may cause hypersensitivity reactions and is extremely expensive. This study was aimed at evaluating whether titrating rituximab to circulating CD20 B cells may improve safety and limit costs of treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research